Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee

British Journal of Cancer

Volumn 115, Issue 1, 2016, Pages 90-94

  Turner, Emma L ^a   Metcalfe, Chris ^a   Donovan, Jenny L ^a   Noble, Sian ^a   Sterne, Jonathan A C ^a   Lane, J Athene ^a   Walsh, Eleanor I ^a   Hill, Elizabeth M ^a   Down, Liz ^a   Ben Shlomo, Yoav ^a   Oliver, Steven E ^b   Evans, Simon ^c   Brindle, Peter ^d   Williams, Naomi J ^a   Hughes, Laura J ^e   Davies, Charlotte F ^a   Ng, Siaw Yein ^a   Neal, David E ^f   Hamdy, Freddie C ^f   Albertsen, Peter ^g   Reid, Colette M ^h   Oxley, Jon ⁱ   McFarlane, John ^c   Robinson, Mary C ^j   Adolfsson, Jan ^k   Zietman, Anthony ^l   Baum, Michael ^m   Koupparis, Anthony ⁱ   Martin, Richard M ^a,n   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

^d Avon Primary Care Research Collaborative   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^h BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

ⁱ SOUTHMEAD HOSPITAL   (United Kingdom)

^j ROYAL VICTORIA INFIRMARY   (United Kingdom)

^k KAROLINSKA INSTITUTE   (Sweden)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

cause of death; cluster randomised controlled trial; death certification; prostate cancer; prostate cancer mortality; screening; sensitivity; specificity

Indexed keywords

ACCURACY; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CAUSE OF DEATH; CODING; DEATH CERTIFICATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; CONTROLLED STUDY; MORTALITY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

AGED; CAUSE OF DEATH; DEATH CERTIFICATES; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84973137297     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.162     Document Type: Article

References (14)

1. Albertsen PC, Walters S, Hanley JA. (2000). A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 163: 519-523
2. Barry MJ, Andriole GL, Culkin DJ, Fox SH, Jones KM, Carlyle MH, Wilt TJ. (2013). Ascertaining cause of death among men in the prostate cancer intervention versus observation trial. Clin Trials 10: 907-914
3. Black WC, Haggstrom DA, Welch HG. (2002). All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94: 167-173
4. Clopper CJ, Pearson ES. (1934). The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26: 404-413
5. de Koning HJ, Blom J, Merkelbach JW, Raaijmakers R, Verhaegen H, Van VP, Nelen V, Coebergh JW, Hermans A, Ciatto S, Makinen T. (2003). Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 92(Suppl 2): 71-78
6. Feuer EJ, Merrill RM, Hankey BF. (1999). Cancer surveillance series: interpreting trends in prostate cancer-part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91: 1025-1032
7. Godtman R, Holmberg E, Stranne J, Hugosson J. (2011). High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol 45: 226-232
8. Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy FC. ProtecT study group. (2014). Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 15: 1109-1118
9. Makinen T, Karhunen P, Aro J, Lahtela J, Maattanen L, Auvinen A. (2008). Assessment of causes of death in a prostate cancer screening trial. Int J Cancer 122: 413-417
10. Miller AB, Feld R, Fontana R, Gohagan JK, Jatoi I, Lawrence Jr. W, Miller A, Prorok PC, Rajput A, Sherman M, Welch G, Wright P, Yurgalevitch S, Albertsen P. (2015). Changes in and impact of the death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Rev Recent Clin Trials 10: 206-211
11. Miller AB, Yurgalevitch S, Weissfeld JL. (2000). Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21: 400S-406S
12. Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, Avery KN, Down L, Walsh E, Davis M, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Hill EM, Davies C, Ng SY, Neal DE, Hamdy FC, Martin RM. CAP trial group. (2014). Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). Br Jf Cancer 110: 2829-2836
13. UK National Screening Committee. (2015). Screening for Prostate Cancer Review 2014 Update: Review Against Programme Appraisal Criteria for the UKNSC
14. Williams NJ, Hill EM, Ng SY, Martin RM, Metcalfe C, Donovan JL, Evans S, Hughes LJ, Davies CF, Hamdy FC, Neal DE, Turner EL. (2015). Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial-lessons learnt from CAP (Cluster randomised triAl of PSA testing for prostate cancer). BMC Med Res Methodol 15: 6